
Cognition Therapeutics, Inc.: updates and filings
Price
$0.58
November 20, 2026Market cap $55M
What Ploutos Investor adds for Cognition Therapeutics
Part of Ploutos Investor, €9.99 a month
- The full history: 6 fiscal years, from 2020
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
What comes next, and what happened
Its next results and latest dividend, and the filings that told of something: results, deals, people, debt. In plain words, each linked to the filing.
Next results
last Aug 6, 2026next Feb 5, 2027
An estimate from when it has reported before, which has been regular. The company announces the date itself.
November 2026
October 2026
August 2026
May 2026
Its SEC filings
What it has filed lately, newest first, linked to the document itself.
- Nov 5, 2026Quarterly reportfor the period to Sep 30, 2026Form10-Q
- Nov 5, 2026Results of operations, delisting noticeForm8-K
- Oct 22, 2026Other material eventsForm8-K
- Aug 7, 2026Quarterly reportfor the period to Jun 30, 2026Form10-Q
- Aug 6, 2026Results of operationsForm8-K
- Jun 24, 2026Other material eventsForm8-K
- Jun 18, 2026Shareholder voteForm8-K
- Jun 4, 2026Regulation FD disclosureForm8-K
- May 21, 2026Other material eventsForm8-K
- May 8, 2026Quarterly reportfor the period to Mar 31, 2026Form10-Q
- May 7, 2026Results of operationsForm8-K
- Apr 27, 2026Annual report to shareholdersfor the period to Dec 31, 2025FormARS
- Apr 27, 2026Additional annual meeting materialFormDEFA14A
- Apr 27, 2026Annual meeting proxy statementFormDEF 14A
- Mar 26, 2026Shares registered for employeesFormS-8
- Mar 26, 2026Annual reportfor the period to Dec 31, 2025Form10-K
- Mar 26, 2026Results of operations, Regulation FD disclosureForm8-K
- Mar 2, 2026Other material eventsForm8-K
- Jan 27, 2026Other material eventsForm8-K
- Dec 23, 2025FilingFormEFFECT
- Dec 22, 2025Correspondence with the SECFormCORRESP
- Dec 18, 2025Material agreement entered, material agreement endedForm8-K
- Dec 18, 2025Shelf registration for future offeringsFormS-3
- Nov 6, 2025Quarterly reportfor the period to Sep 30, 2025Form10-Q
- Nov 6, 2025Results of operationsForm8-K
| Filed | Form | What it is | Filing |
|---|---|---|---|
| Nov 5, 2026 | 10-Q | Quarterly reportfor the period to Sep 30, 2026 | Document |
| Nov 5, 2026 | 8-K | Results of operations, delisting notice | Document |
| Oct 22, 2026 | 8-K | Other material events | Document |
| Aug 7, 2026 | 10-Q | Quarterly reportfor the period to Jun 30, 2026 | Document |
| Aug 6, 2026 | 8-K | Results of operations | Document |
| Jun 24, 2026 | 8-K | Other material events | Document |
| Jun 18, 2026 | 8-K | Shareholder vote | Document |
| Jun 4, 2026 | 8-K | Regulation FD disclosure | Document |
| May 21, 2026 | 8-K | Other material events | Document |
| May 8, 2026 | 10-Q | Quarterly reportfor the period to Mar 31, 2026 | Document |
| May 7, 2026 | 8-K | Results of operations | Document |
| Apr 27, 2026 | ARS | Annual report to shareholdersfor the period to Dec 31, 2025 | Document |
| Apr 27, 2026 | DEFA14A | Additional annual meeting material | Document |
| Apr 27, 2026 | DEF 14A | Annual meeting proxy statement | Document |
| Mar 26, 2026 | S-8 | Shares registered for employees | Document |
| Mar 26, 2026 | 10-K | Annual reportfor the period to Dec 31, 2025 | Document |
| Mar 26, 2026 | 8-K | Results of operations, Regulation FD disclosure | Document |
| Mar 2, 2026 | 8-K | Other material events | Document |
| Jan 27, 2026 | 8-K | Other material events | Document |
| Dec 23, 2025 | EFFECT | Filing | Document |
| Dec 22, 2025 | CORRESP | Correspondence with the SEC | Document |
| Dec 18, 2025 | 8-K | Material agreement entered, material agreement ended | Document |
| Dec 18, 2025 | S-3 | Shelf registration for future offerings | Document |
| Nov 6, 2025 | 10-Q | Quarterly reportfor the period to Sep 30, 2025 | Document |
| Nov 6, 2025 | 8-K | Results of operations | Document |
From the company's record at the SEC (EDGAR). The topics of each 8-K are the item codes the company itself filed. Its whole record at the SEC, since Jan 29, 2009.
The full analysis
What do Cognition Therapeutics's filings show?
The filings are where every one of Cognition Therapeutics's figures comes from. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.